REVBIO
RevBio is commercializing an injectable, self-setting, osteoconductive bone adhesive biomaterial that can bond bone to bone and bone to metal in a wet field environment. The company's showcase product, Tetranite, is being reviewed by the FDA for a growing body of applications including oral, craniofacial, orthopedic, and neurosurgical indications. Over time, this synthetic adhesive biodegrades and is replaced by new bone. This unique material will reduce the duration and complexity of medical procedures, allow for more minimally invasive surgeries, and will improve patient outcomes by reducing recovery time and the overall cost of care.
REVBIO
Industry:
Biotechnology Health Care Medical Medical Device
Founded:
2014-07-16
Address:
Lowell, Massachusetts, United States
Country:
United States
Website Url:
http://www.revbio.com
Total Employee:
11+
Status:
Active
Contact:
617-947-6246
Email Addresses:
[email protected]
Total Funding:
30.26 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS YouTube AWS Global Accelerator
Current Advisors List
Current Employees Featured
Founder
Investors List
MedTech Innovator
MedTech Innovator investment in Non Equity Assistance - RevBio
National Institute on Aging
National Institute on Aging investment in Grant - RevBio
Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center
Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center investment in Grant - RevBio
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - RevBio
National Institute of Health – HEAL
National Institute of Health – HEAL investment in Grant - RevBio
Delta Dental of Rhode Island
Delta Dental of Rhode Island investment in Convertible Note - RevBio
Boston Harbor Angels
Boston Harbor Angels investment in Convertible Note - RevBio
Ariel Southeast Angel Partners
Ariel Southeast Angel Partners investment in Convertible Note - RevBio
Beacon Angels
Beacon Angels investment in Convertible Note - RevBio
Delta Dental of Washington
Delta Dental of Washington investment in Convertible Note - RevBio
Official Site Inspections
http://www.revbio.com
- Host name: 192.0.78.132
- IP address: 192.0.78.132
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "RevBio"
REVBIO TETRANITE IS A NOVEL REGENERATIVE ADHESIVE …
RevBio was started with one goal in mind—to end medicine’s 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, …See details»
About RevBio - REVBIO
Headquartered in Lowell, the company includes an extensive team of scientists, engineers, and clinicians who have reverse engineered a mineral-organic compound into a patented bioadhesive with an extensive platform of bone …See details»
RevBio, Inc. - LinkedIn
RevBio, Inc. | 2,438 followers on LinkedIn. Transforming Bone Repair | RevBio was started with one goal in mind—to end medicine’s 50 year search for a biocompatible bone adhesive.See details»
RevBio - Crunchbase Company Profile & Funding
RevBio is commercializing an injectable, self-setting, osteoconductive bone adhesive biomaterial that can bond bone to bone and bone to metal in a wet field environment. The company's …See details»
RevBio Bone Adhesive to Fly on SpaceX CRS-26 - ISS National Lab
Nov 15, 2022 · To help patients recover quicker, RevBio developed a potential new therapeutic device, a patented bone adhesive called Tetranite®, that promotes bone growth.See details»
Brian Hess - CEO & Founder at RevBio - The Org
Brian founded RevBio in 2014 with the goal of commercializing Tetranite®, a regenerative bone adhesive with 6+ patents. The game changing biomaterial platform promises to transform …See details»
LaunchPad Medical Rebrands as RevBio and Launches an Updated …
LOWELL, Mass., Aug. 4, 2020 /PRNewswire/ -- Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more …See details»
RevBio Awarded a $3.4 Million NIH Grant for Its Novel …
Oct 6, 2023 · RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and …See details»
RevBio Receives FDA Approval to Conduct a First-in-Human …
Dec 8, 2023 · RevBio, Inc ., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and …See details»
FDA Approves First-in-Human Trial for RevBio's Regenerative Bone ...
Mar 22, 2024 · RevBio Inc. has received U.S. Food and Drug Administration approval to start a 20-patient pilot clinical trial to examine the safety and efficacy of its bone adhesive …See details»
RevBio Receives NIH Grant to Explore the Treatment of Vertebral ...
Sep 20, 2022 · RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and …See details»
RevBio Awarded a $3.4 Million NIH Grant for Its Novel ... - BioSpace
Oct 6, 2023 · RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and …See details»
Brian Hess, CEO and Founder - Musculoskeletal New Ventures …
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone …See details»
RevBio Receives FDA Approval to Conduct a First-in-Human
Dec 8, 2023 · RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the …See details»
RevBio Receives FDA Approval to Conduct a First-in-Human …
LOWELL, Mass., December 08, 2023 -- (BUSINESS WIRE)--RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot …See details»
NIH Awards RevBio $3.4M Grant to Develop its Regenerative Bone …
Dec 14, 2023 · RevBio Inc. has been awarded a three-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health, to further develop its TETRANITE …See details»
RevBio Receives FDA Approval to Conduct a First-in-Human …
Dec 8, 2023 · RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and …See details»
RevBio Launches an Experiment for its Regenerative Biomaterial …
Dec 9, 2022 · RevBio, Inc., announced that an experiment to study TETRANITE®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the …See details»
Press Releases - REVBIO
December 8th 2023– RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation. October 25th 2023– RevBio …See details»
Security Vulnerabilities fixed in Firefox 133 — Mozilla
3 days ago · Work for a mission-driven organization that makes people-first products. Mozilla Blog. Learn about Mozilla and the issues that matter to us. Impact. Find out how we’re making …See details»